Copenhagen, Denmark; July 12, 2002 - Genmab A/S (CSE: GEN and Neuer Markt: GE9D) and JARI Pharmaceuticals BV, a privately held Dutch company, announced today an alliance to develop new antibody therapeutic products. Under the partnership JARI will provide novel commercially promising disease targets and Genmab will utilize its fully human antibody technology to create and develop new products.

The alliance will cover a range of disease areas within the inflammation area. The collaboration brings together Genmab’s broad antibody development capabilities and extensive array of pre-clinical tools to generate and characterise fully human antibodies and JARI’s skills in finding novel targets related to inflammatory diseases. Genmab and JARI will collaborate on the research, development and any eventual commercialization of the new antibody products and will share equally the development costs and revenues generated from out-licensing or sales of these products.

“Genmab is strongly pursuing its strategy of creating a broad based product portfolio as we announce this, our fifth partnership for disease targets this year.” said Lisa N Drakeman Ph.D, Genmab’s Chief Executive Officer. “We are happy to add JARI Pharmaceuticals to our growing list of partners which will enable us to bring urgently needed antibody treatments to patients”

"JARI is delighted to collaborate with Genmab, a company recognised internationally as a leader in its field”, said Jaap Kampinga MD, CEO of JARI Pharmaceuticals BV. “This collaboration supports JARI’s strategy to combine strengths in developing innovative therapeutics for inflammatory diseases utilising our LANTIS drug discovery programme for finding promising drug leads from unique natural sources.”